BR112018067330A2 - método para o tratamento de paciente com carga tumoral - Google Patents

método para o tratamento de paciente com carga tumoral

Info

Publication number
BR112018067330A2
BR112018067330A2 BR112018067330A BR112018067330A BR112018067330A2 BR 112018067330 A2 BR112018067330 A2 BR 112018067330A2 BR 112018067330 A BR112018067330 A BR 112018067330A BR 112018067330 A BR112018067330 A BR 112018067330A BR 112018067330 A2 BR112018067330 A2 BR 112018067330A2
Authority
BR
Brazil
Prior art keywords
tumor burden
treating patient
signaling inhibitor
patient
treating
Prior art date
Application number
BR112018067330A
Other languages
English (en)
Inventor
Hunt Hazel
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of BR112018067330A2 publication Critical patent/BR112018067330A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

esta invenção proporciona método que combina um inibidor de sinalização e um modulador do receptor de glucocorticoides para tratar o câncer, por exemplo, câncer sensível ao inibidor de sinalização.
BR112018067330A 2016-03-01 2017-02-28 método para o tratamento de paciente com carga tumoral BR112018067330A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302106P 2016-03-01 2016-03-01
US201662320276P 2016-04-08 2016-04-08
PCT/US2017/019948 WO2017151613A1 (en) 2016-03-01 2017-02-28 The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

Publications (1)

Publication Number Publication Date
BR112018067330A2 true BR112018067330A2 (pt) 2019-01-22

Family

ID=59744340

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067330A BR112018067330A2 (pt) 2016-03-01 2017-02-28 método para o tratamento de paciente com carga tumoral

Country Status (15)

Country Link
US (2) US10980797B2 (pt)
EP (1) EP3423453A4 (pt)
JP (3) JP6847120B2 (pt)
KR (1) KR20180116372A (pt)
CN (1) CN109071537A (pt)
AU (1) AU2017228329B2 (pt)
BR (1) BR112018067330A2 (pt)
CA (1) CA3015218A1 (pt)
CL (1) CL2018002467A1 (pt)
IL (2) IL297201A (pt)
MX (1) MX2018010564A (pt)
PH (1) PH12018501848A1 (pt)
SG (1) SG11201807421TA (pt)
WO (1) WO2017151613A1 (pt)
ZA (1) ZA201805787B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
WO2018183947A1 (en) * 2017-03-31 2018-10-04 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
CA3065555A1 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
EP3858359B1 (en) 2018-09-28 2024-03-06 Kyungpook National University Industry-Academic Cooperation Foundation Composition, comprising a thiamine derivative, for prevention or treatment of hypercortisolemia
KR102651146B1 (ko) * 2018-11-09 2024-03-25 코어셉트 쎄라퓨틱스 인코포레이티드 뇌하수체 종양을 축소시키는 방법
CN117281790A (zh) * 2018-12-19 2023-12-26 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
JP2022523376A (ja) 2019-02-22 2022-04-22 コーセプト セラピューティクス， インコーポレイテッド レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途
JP2022552422A (ja) * 2019-10-16 2022-12-15 コーセプト セラピューティクス， インコーポレイテッド 選択的グルココルチコイド受容体拮抗物質を用いてがん患者における好中球／リンパ球比を正常化する方法
KR20220133275A (ko) * 2020-01-29 2022-10-04 코어셉트 쎄라퓨틱스 인코포레이티드 선택적 글루코코르티코이드 수용체 조절제 (sgrm) 및 항체 체크포인트 억제제를 사용한 부신피질 암종의 치료
CN115397418A (zh) * 2020-02-10 2022-11-25 科赛普特治疗学股份有限公司 使用选择性糖皮质激素受体调节剂刺激抗肿瘤反应的方法
EP4157275A4 (en) * 2020-05-27 2024-06-05 Corcept Therapeutics Inc CONCOMITANT ADMINISTRATION OF GLUCOCORTICOID RECEPTOR MODULATOR RELACORILANT AND CYP3A SUBSTRATES
US20210369689A1 (en) * 2020-05-27 2021-12-02 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c9 substrates
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2023102569A1 (en) * 2021-12-03 2023-06-08 Board Of Regents, The University Of Texas System Glucocorticoid receptor blockade with mifepristone to sensitize pancreatic cancer to immunotherapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101185281B1 (ko) 2004-03-09 2012-09-21 코어셉트 쎄라퓨틱스, 잉크. 융합 고리 아자데칼린 글루코코르티코이드 수용체 조절물질
ES2531040T3 (es) 2009-05-12 2015-03-10 Corcept Therapeutics Inc Formas sólidas y procedimiento de preparación
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
JP2014509592A (ja) * 2011-03-15 2014-04-21 アッヴィ・インコーポレイテッド 核ホルモン受容体モジュレーター
WO2013039916A1 (en) * 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
RU2672874C2 (ru) * 2011-10-04 2018-11-20 Инвайвис Фармасьютикалз Инк. Способы и системы для выявления и лечения опухолей, восприимчивых к антипрогестинам
WO2013169971A1 (en) * 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EP2854814B1 (en) 2012-05-25 2018-01-31 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JP6508785B2 (ja) * 2013-10-25 2019-05-08 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
ES2862139T3 (es) * 2013-11-11 2021-10-07 Armo Biosciences Inc Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
WO2015077414A1 (en) * 2013-11-20 2015-05-28 Dana-Farber Cancer Institute, Inc. Kynurenine pathway biomarkers predictive of anti-immune checkpoint inhibitor response
EP3848027B1 (en) * 2013-11-25 2023-04-05 Corcept Therapeutics Incorporated Octahydro fused azadecalin glucocorticoid receptor modulators
CN106456724A (zh) * 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
PE20160844A1 (es) 2013-12-24 2016-09-03 Bristol Myers Squibb Co Compuestos triciclicos como agentes anticancerigenos
JP6652557B2 (ja) 2014-05-30 2020-02-26 ヴェンタナ メディカル システムズ， インク． Ｐｄ−ｌ１について染色された腫瘍組織の改善されたスコア化のための多重アッセイ
US20180064679A1 (en) * 2015-03-05 2018-03-08 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor

Also Published As

Publication number Publication date
CN109071537A (zh) 2018-12-21
CL2018002467A1 (es) 2018-11-23
KR20180116372A (ko) 2018-10-24
JP2019023228A (ja) 2019-02-14
EP3423453A4 (en) 2019-11-06
MX2018010564A (es) 2018-11-09
JP6847120B2 (ja) 2021-03-24
WO2017151613A1 (en) 2017-09-08
IL261502A (en) 2018-10-31
IL297201A (en) 2022-12-01
CA3015218A1 (en) 2017-09-08
IL261502B (en) 2022-11-01
EP3423453A1 (en) 2019-01-09
IL261502B2 (en) 2023-03-01
PH12018501848A1 (en) 2019-01-28
US10980797B2 (en) 2021-04-20
US20210205294A1 (en) 2021-07-08
AU2017228329B2 (en) 2021-03-11
JP2023060061A (ja) 2023-04-27
ZA201805787B (en) 2020-05-27
JP2019507159A (ja) 2019-03-14
SG11201807421TA (en) 2018-09-27
US20190083486A1 (en) 2019-03-21
AU2017228329A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
BR112018067330A2 (pt) método para o tratamento de paciente com carga tumoral
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
SV2017005380A (es) Tratamientos conjuntos con anticuerpos anti cd40
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
MX2018008995A (es) Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer.
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
BR112017000130A2 (pt) método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
BR112018015836A2 (pt) administração de células t engenheiradas para tratamento de cânceres no sistema nervoso central
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
CL2019002427A1 (es) Inhibición de smarca2 para el tratamiento de cáncer.
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
BR112019011199A2 (pt) método para tratar um indivíduo que tem um câncer de próstata e kits
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
EA201991818A1 (ru) Лечение рака
MX2020006297A (es) Variantes de cd19.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]